Furthermore, SPMI-HIF2-1 could effectively inhibit tumor progression in subcutaneous and intrarectal nude mouse xenograft models, through a simultaneous degradation of both MDM2 and MDMX and durable p53 activation. Here, MDM4 is linked to neoplasm.